Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Innate and Acquired Resistance to Plasmodium Falciparum Malaria in Mali

Completed

Conditions: Malaria

First Posted Date: 2008-04-29

Last Posted Date: 2019-12-17

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 1718

Registration Number: NCT00669084

Locations: 🇲🇱
University of Bamako, Faculty of Medicine, Pharmacy and Odontostomatology, Bamako, Mali

Bacterial Vaginosis Home Screening to Prevent STDs

Phase 3

Completed

Conditions: Bacterial Vaginosis

Interventions: Drug: Metronidazole

First Posted Date: 2008-04-28

Last Posted Date: 2020-02-18

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 1370

Registration Number: NCT00667368

Locations: 🇺🇸
University of North Carolina School of Medicine - Center for Infectious Diseases, Chapel Hill, North Carolina, United States
🇺🇸
Johns Hopkins Bayview Medical Center - Infectious Diseases, Baltimore, Maryland, United States
🇺🇸
San Francisco Department of Public Health - San Francisco City Clinic, San Francisco, California, United States

and more 4 locations

HIV Screening in the Emergency Department Setting

Not Applicable

Completed

Conditions: HIV Infections

Interventions: Other: Targeted Screening
Other: Routine Screening

First Posted Date: 2008-04-25

Last Posted Date: 2013-02-04

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 9572

Registration Number: NCT00667186

Locations: 🇺🇸
University of Cincinnati Medical Center, Cincinnati, Ohio, United States

Malaria Studies in Cambodia

Completed

Conditions: Malaria

First Posted Date: 2008-04-22

Last Posted Date: 2018-08-20

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 1978

Registration Number: NCT00663546

Locations: 🇰🇭
National Center for Parasitology, Entomology, and Malaria Controk, Ministry of H, Phnom Penh, Cambodia
🇰🇭
Ratanakiri Referral Hospital, Ratanakiri Province, Cambodia
🇰🇭
Preah Vihear Referral Hospital, Preah Vihear Province, Cambodia

Study of Viral Load Decay Rates in HIV Infected Participants Starting Treatment With Raltegravir (RAL) and Emtricitabine/Tenofovir Disoproxil Fumarate (TDF)

Phase 1

Completed

Conditions: HIV Infections

Interventions: Drug: Raltegravir
Drug: Emtricitabine/tenofovir disoproxil fumarate

First Posted Date: 2008-04-18

Last Posted Date: 2021-11-01

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 40

Registration Number: NCT00660972

Locations: 🇺🇸
Northwestern University CRS, Chicago, Illinois, United States
🇺🇸
IHV Baltimore Treatment CRS, Baltimore, Maryland, United States
🇺🇸
Ohio State University CRS, Columbus, Ohio, United States

and more 12 locations

Safety and Immunogenicity of Peru-15-pCTB in Healthy Adult Subjects

Phase 1

Completed

Conditions: Gastroenteritis Escherichia Coli

Interventions: Drug: Ciprofloxacin
Biological: Peru-15-pCTB
Other: Sodium bicarbonate/Ascorbic Acid/Aspartame Buffer

First Posted Date: 2008-04-07

Last Posted Date: 2021-07-29

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 62

Registration Number: NCT00654108

Locations: 🇺🇸
Cincinnati Children's Hospital Medical Center - Infectious Diseases, Cincinnati, Ohio, United States

Poly-ICLC to Prevent Respiratory Viral Infections A Safety Study

Phase 1

Completed

Conditions: Influenza
Severe Acute Respiratory Distress Syndrome
Smallpox
Ebola
Unknown Respiratory Viruses

First Posted Date: 2008-03-28

Last Posted Date: 2018-07-05

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 57

Registration Number: NCT00646152

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Safety of and Immune Response to Recombinant Live-Attenuated Parainfluenza Type 1 Virus Vaccine

Phase 1

Completed

Conditions: Virus Diseases
Parainfluenza

Interventions: Biological: rHPIV1 84/del170/942A, Lot PIV1 #104A vaccine
Biological: Placebo

First Posted Date: 2008-03-21

Last Posted Date: 2013-02-25

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 87

Registration Number: NCT00641017

Locations: 🇺🇸
Center for Immunization Research (CIR), Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States

Nevirapine Study for the Prevention of Maternal-Infant HIV Transmission in Uganda

Phase 3

Completed

Conditions: HIV Infections

Interventions: Drug: Nevirapine
Drug: HIV immune globulin solution

First Posted Date: 2008-03-20

Last Posted Date: 2008-04-02

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 722

Registration Number: NCT00639938

Safety of and Immune Response to an Adenoviral HIV-1 Vaccine in Healthy Adults

Phase 1

Completed

Conditions: HIV Infections

Interventions: Biological: Ad26.ENVA.01 HIV-1 vaccine

First Posted Date: 2008-02-20

Last Posted Date: 2021-11-01

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 60

Registration Number: NCT00618605

Locations: 🇺🇸
Brigham and Women's Hosp. Novel Adenoviral Vector Prophylactic HIV Vaccine Non-Network CRS, Boston, Massachusetts, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy